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EDITORIAL
Computed Tomography Screening for Lung Cancer
without a Smoking Cessation Program—Not a
Cost-Effective Idea
W. K. Evans, MD, FRCPC, and Michael C. Wolfson, PhD
It is hard not to be excited by the recently reported results of the National Lung ScreeningTrial (NLST).1 Although advances have been made in the surgical, radiotherapeutic, and
chemotherapeutic management of lung cancer over the past several decades, the long-term
survival rate for lung cancer remains very low.2 The 20% reduction in mortality observed
in this large randomized multicenter lung cancer screening study with low-dose computed
tomography (CT) (20% of the usual dose) compared with chest x-ray in high-risk
individuals (30 or more pack-years smokers or former smokers who had quit smoking
within 15 years of study entry and currently 55–74 years of age) is definitely something
to celebrate. But is population-based lung cancer screening really ready for prime time?
Despite the positive NLST result, we do not yet know how optimally to define the
“at-risk” population, when to start screening, what screening interval to use,3 and for how
long. Moreover, there is the issue of the cost of a population-based screening program and
its cost-effectiveness compared with other lung cancer control strategies.
In an increasingly cost-constrained world, this issue has to be confronted. When breast
cancer screening was first introduced, over two decades ago, there were no calls for
cost-effectiveness analyses before its implementation on a population basis, but times are
different now. National economies cannot continue to absorb the cost of new health
technologies without a thoughtful examination of the value for money proposition. This
was recognized by the International Association for the Study of Lung Cancer CT
Screening Task Force which recommended that the cost-effectiveness of CT screening
needed to be examined before it is implemented at the national level.4
The article by McMahon et al.5 addresses the issue of cost-effectiveness using an
existing Lung Cancer Policy Model which simulates lung cancer development, disease
progression, detection, treatment, and survival. The lung cancer natural history parameters
in the model have been calibrated against US tumor registry data on age-specific cancer
incidence rates; on the distribution by size, stage, and cell types of incident lung cancers;
and by lung cancer-specific survival. The model simulates symptomatic, incidental, and
screen-detected benign and malignant pulmonary nodules. The sensitivity of screening CT
examinations was adjusted for nodule size and location of the nodule in the chest. In the
base case, nodules less than 4 mm were not followed but those between 4 and 6 mm had
serial high-resolution CT scans at 9 and 24 months and those 6 to 8 mm were scheduled
for CT at 6, 12, and 24 months. In sensitivity analyses, fewer high-resolution CT
examinations were simulated. Nodules greater than 8 mm were biopsied. Survival was
modeled as a function of treatment and underlying disease characteristics. Treatment
followed National Comprehensive Cancer Network consensus guidelines in place in 2000.
The model simulated the life-time histories of individuals in each of six cohorts (500,000
histories per cohort) defined by age and gender (males and females; age 50, 60, or 70
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years) and incorporated the smoking histories of the US
population in 1990. A background rate of smoking cessation
of 3% for current smokers was included in the model.
Importantly, the effects of smoking cessation with therapy
consisting of bupropion and nicotine replacement therapy
were incorporated and a range of posited effects on 1-year
smoking abstinence rates were explored from 1.5% (i.e.,
lower than the assumed baseline, on the assumption that a
negative screen might make the person less likely to quit) to
4%, 8%, 16%, or 30%. Costs of diagnostic tests were esti-
mated based on Medicare payments in 2006, and treatment
costs by phase of care were incorporated from the period
1992–2003.6 The cost per quality-adjusted life-year (QALY)
gained was estimated for CT screening, smoking cessation
alone, and for a combined program of CT screening and
smoking cessation. A societal perspective was used in the
economic analysis, and patient time and caregiver time costs
were included.
As with any simulation model, the outputs and any
conclusions that are drawn from them are only as good as
the assumptions that are made in model development. How-
ever, in several respects, the assumptions in the McMahon
model are in line with what is likely to occur in the real world
if CT screening is adopted. The authors simulated annual CT
screening in a broader population of smokers—both younger
(age 50 years to start screening) and with less cumulative
smoking history (20 pack-years)—than NLST. Unlike the
NLST with its three CT examinations, McMahon et al. have
modeled annual CT examination which is what clinicians
would likely adopt in the absence of better guidance. How-
ever, annual low-dose CT examinations combined with diag-
nostic CT examinations to investigate nodules could expose
the screened population to the risk of radiation-induced lung
cancer. This risk has been incorporated into the model pro-
viding an estimate of one of the potential harms of a CT
screening program.
The assumptions around compliance with CT screening
appear more realistic in the McMahon model. In the NLST,
adherence to screening was more than 90%. In the simulation,
70% of eligible individuals adhered to their screening sched-
ule. This estimate of compliance is probably still high given
the fact that there are significant challenges in reaching
current smokers, among whom are those most heavily ad-
dicted. Those who have quit smoking may be more motivated
to attend for screening, but getting former and current smok-
ers into a screening program and compliant with the screen-
ing interval will undoubtedly prove to be a significant imple-
mentation challenge.
It is easy to be critical of the current model. It uses the
smoking history of Americans two decades ago although
smoking frequency has declined since then.7 Treatment was
simulated using guidelines in place in 2000 before the general
use of positron emission tomography/CT scanning for diag-
nosis of solitary pulmonary nodules or staging of lung cancer
and the use of many of the newer (and expensive) chemo-
therapy agents and molecular targeted therapies. The costs of
diagnostic procedures were based on Medicare reimburse-
ment levels and are lower and probably in some cases much
lower than the prices that would be charged to private payers.
Treatment costs were based on patterns of care and costs of
treatment in the 1992–2003 timeframe. Nonetheless, several
key messages can be derived from the microsimulation model
that should influence the thinking of those proposing popu-
lation-based screening programs.
McMahon et al. implicitly assume that the benefits of
CT screening as demonstrated in NLST can be extended to a
younger age group than was included in NLST and that
annual screening of persons with even a 20 pack-year smok-
ing history has the potential to reduce lung cancer-specific
mortality. These assumptions will need evidentiary support
before population-based CT screening eligibility is broad-
ened. The model projects a reduction of 18 to 25% at 10 years
at a cost of $126,000 to $269,000/QALY. When radiation-
induced lung cancer is included, the mortality reductions are
smaller and the costs higher. Restricting screening to higher
risk individuals with at least 40 pack-years and annual screen-
ing with perfect adherence yields improved cost-effectiveness
ratios in the range of $110,000 to $166,000/QALY. With a
70% adherence rate, the incremental cost-effectiveness ratio
compared with no screening is $280,000/QALY. The authors
do not comment on whether they see such a high cost-
effectiveness ratio as a barrier to the adoption of CT screen-
ing. Certainly, in comparison to the overused and out-of-date
cost-effectiveness ratio of $50,000/QALY commonly applied
in the context of new drug approvals, the cost/QALY of CT
screening is very high. In comparison to both breast and
colorectal screening with cost-effective ratios of $47,700/
QALY (2006$) and $13,000 to $32,000/QALY, respectively,
lung cancer screening is much less cost-effective despite hav-
ing the advantage of being able to focus on individuals at
higher risk of disease.8,9
However, the most important message of this article is
not included in its title. Smoking cessation alone is substan-
tially more cost-effective than CT screening alone and is
more cost-effective than smoking cessation combined with
CT screening albeit with greater benefits. The model predicts
that in a cohort of 50-year-olds, if the smoking cessation rate
doubled to 6% from a background rate of 3%, it would cost
$17,700 to 20,800/QALY for men and women, respectively.
If smoking cessation is combined with annual screening, it
would also be more cost-effective for men ($73,000/QALY)
and women ($40,000/QALY) than CT screening alone. That
smoking cessation is far more cost-effective than CT screen-
ing either alone or in combination has very important impli-
cations for how screening programs are organized in the
future. Clearly, no CT screening program should be mounted
without being tightly linked to a smoking cessation program.
A focus on the technology alone (low-dose CT screening)
without seizing the opportunity to modify the behavior of
smokers who enter the program will result in a program that
has less impact on mortality reduction and one that is less
cost-effective. Furthermore, the model demonstrates that if
the introduction of lung CT screening programs were to result
in current smokers believing that screening absolves them of
the need to stop smoking, the overall effect could be very
adverse.
Evans and Wolfson Journal of Thoracic Oncology • Volume 6, Number 11, November 2011
Copyright © 2011 by the International Association for the Study of Lung Cancer1782
REFERENCES
1. The National Lung Screening Trial Research Team, Aberle DR,
Adams AM, Berg CD, et al. Reduced lung-cancer mortality with
low-dose computed tomographic screening. N Engl J Med 2011;365:
395– 409.
2. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin
2010;60:277–300; Erratum in CA Cancer J Clin 2011;61:133–134.
3. Tammemagi MC, Lam S, McWilliams A, et al. Incremental value of
pulmonary function and sputum DNA image cytometry in lung cancer
risk prediction. Cancer Prev Res 2011;4:552–561.
4. IASLC’S 2011 Statement on CT Screening for Lung Cancer. Available at:
http://iaslc.technetrics.com/policies/statement-on-ct-screening/.
Accessed August 15, 2011.
5. McMahon P, Kong CY, Bouzan C, et al. Cost-effectiveness of CT screening
for lung cancer in the U.S. J Thorac Oncol 2011;6:1841–1848.
6. Cipriano LE, Romanus D, Earle CC, et al. lung cancer treatment costs,
including patient responsibility, by disease stage and treatment modality,
1992– to 2003. Value Health 2010;14:41–52.
7. Rock VJ, Malarcher A, Kahende JW, et al. Cigarette smoking among
adults—United States 2006. MMWR Morb Mortal Wkly Rep 2007;56:
1157–1161.
8. Stout NK, Rosenverg MA, Trentham-Dietz A, et al. Retrospective
cost-effectiveness analysis of screening mammography. J Natl Cancer
Inst 2006;98:774–782.
9. Pignone M, Saha S, Hoerger T, et al. Cost-effectiveness analyses of
colorectal cancer screening: a systematic review for the U.S. Preventive
Services Task Force. Ann Intern Med 2002;137:96–104.
Journal of Thoracic Oncology • Volume 6, Number 11, November 2011 CT Lung Cancer Screening without Smoking Cessation
Copyright © 2011 by the International Association for the Study of Lung Cancer 1783
